tirzepatide trial is finally here – what's the big deal? – GP Voice Overview of the SURPASS phase

The evolution from 2023 to 20242025 represents a movement from precautionary cessation to continuation with risk mitigation, reflecting a more sophisticated understanding of risk-benefit profiles [47]

This assessment helps determine whether weight loss injections are appropriate and establishes realistic expectations for treatment outcomes and duration

Thus, although we found the rates of heptanoate oxidation were fairly low compared with octanoate, this might be the result of our assay, which measures complete oxidation, not necessarily reflecting anaplerosis

Considering the FP and TN, we can see our RKHS model is still producing significantly more sparser model than [25]s model